PROVIDER PROFILE · NPI 1659318095

Carl NueschMD

PRACTICEONCOLOGY PHARMACY SERVICES, INCSee all providers at this practice →

Radiation OncologyAustin, TXI

MEDICARE UTILIZATION · PART B · 2024

Total beneficiaries

1,398

Unique beneficiaries

—

Total services

16,236

Distinct HCPCS

Medicare payment

$802K

Peer benchmark

Total Medicare services vs. 329 Radiation Oncology providers in TX — top quintile (cohort median 1,836).

PRESCRIBING · PART D · 2024

Total Rx claims

Beneficiaries

—

Total drug cost

$438

Distinct drugs

Brand share

61.5%

Top prescribed drugs

Prochlorperazine Maleate15 claims

Ondansetron12 claims

Silver Sulfadiazine12 claims

QUALITY · MIPS · 2024

Final MIPS score

85.1

Quality

67.5

Cost

0.0

Improvement activities

40.0

Promoting interop.

100.0

Payment adjustment

0.43%

APM Entity

INDUSTRY PAYMENTS · OPEN PAYMENTS · 2024

No data available for this provider in 2024.

REFERRAL NETWORK

Where Carl Nuesch's patients come from & go

Directional shared-patient flow from Medicare claims — who sends patients to this provider (inbound) and where this provider's patients go next (outbound). 6 inbound referrers · 0 outbound destinations.

Receives referrals from

Inbound — who sends patients here

Physician	Patients	Visits
Clinical Pathology Laboratories, Inc. Clinical Laboratory · Austin, TX	33	460
ASCENSION SETON	24	174
Debra Patt Medical Oncology · Austin, TX	21	2,589
Jane Chawla Hematology-Oncology · Austin, TX	14	855
Simon Trubek Diagnostic Radiology · Austin, TX	13	166
Jeffrey Yorio Hematology-Oncology · Austin, TX	12	1,360

Refers patients to

Outbound — where patients go next

No outbound pairs above the suppression threshold.

Source: CMS Physician Shared Patient Patterns (30-day window, Medicare FFS). Direction = a beneficiary seen by the first provider, then the second, within 30 days; a proxy for referral, not a documented referral. Pairs with fewer than 11 shared beneficiaries are suppressed.

CROSS-REFERENCE

Related data on other Healthparse brands

ProviderScore

OIG/SAM exclusion screening, sanctions history